Navigation Links
WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
Date:6/28/2009

SHANGHAI, June 29 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that it had been selected by China's Ministry of Commerce to the list of Top Ten Leading Outsourcing Enterprises in China. The list was announced at the Second Annual China International Service Outsourcing Cooperation Conference, held in Nanjing on June 23 and 24, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

According to the ministry, revenue generated by Chinese outsourcing companies in 2008 grew 34% year over year to $1.5 billion. The top ten companies produced almost one third of that revenue. Those companies represented the healthcare, service and manufacture, government, education and finance sectors. WuXi PharmaTech was the only winner in healthcare.

"We are honored to receive this recognition by the Ministry of Commerce," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Outsourcing benefits not only China by tapping the skills and talents of our country's productive workforce, but also benefits countries around the world with high-quality, cost-effective products and services provided by outsourcing service companies. We are grateful to the Ministry of Commerce for its generous support of WuXi and the outsourcing industry in general. With continued support, we will continue to develop both capabilities and capacity to better serve the world's leading life science companies."

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, we provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners to improve the success of research and shorten the time of development cost effectively in discovering and developing drugs and medical devices.

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
2. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
3. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
4. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
5. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
7. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
8. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
9. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
10. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
11. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... This report analyzes the worldwide markets for Biostimulants ... Amino, & Fulvic), Extract Based, and Others. The report also ... & Turf, Row Crops, and Others. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and forecasts are ...
(Date:12/8/2016)... 8, 2016  Biotheranostics today announced that new ... the Breast Cancer Index (BCI) in identifying which ... most at-risk for disease recurrence and might benefit ... three studies advancing the understanding of the value ... biology and inform decisions related to patient treatment. ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
(Date:12/8/2016)... Francisco, CA (PRWEB) , ... December 08, 2016 ... ... Oculus as finalists in the World Technology Awards. uBiome is one of just ... received across all categories. , In addition to uBiome, companies nominated as finalists ...
Breaking Biology Technology:
(Date:11/29/2016)... 29, 2016 BioDirection, a privately held medical ... the objective detection of concussion and other traumatic brain ... completed a meeting with the U.S. Food and Drug ... Pre-Submission Package. During the meeting company representatives reviewed plans ... precursor to commencement of a planned pilot trial. ...
(Date:11/29/2016)... 29, 2016 Nearly one billion matches per second ... ... DERMALOG is Germany's ... efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today ... athletes and their trainers non-invasively measure hemoglobin, ... Pulse Rate, and Respiration Rate in approximately 30 seconds. ... users easy and immediate access to key data about ... of a training regimen. Hemoglobin carries ...
Breaking Biology News(10 mins):